Please assess the completion status of the following clinical trial:

Trial Title: CHAMP: Study of NVK-002 in Children With Myopia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Children aged 3 to ≤ 17.0 years.~2. Myopia SER of at least -0.50 D and no worse than -6.00 D myopia in each eye as measured by cycloplegic autorefraction.~Exclusion Criteria:~1. If present, astigmatism more than -1.50 D in either eye.~2. Current or history of amblyopia or strabismus.~3. History of any disease or syndrome that predisposes the subject to severe myopia (e.g., Marfan syndrome, Stickler syndrome, retinopathy of prematurity).~4. History in either eye of abnormal ocular refractive anatomy (e.g., keratoconus, lenticonus, spherophakia).~5. Serious systemic illness that, in the Investigator's opinion, would render the subject ineligible.~6. Chronic use (more than 3 days per week) of any topical ophthalmic medications (prescribed or over the-counter) other than the assigned study medication.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- NVK-002 Concentration 1 (Type: EXPERIMENTAL): Stage 1: Subjects will be randomized to NVK-002 Concentration 1~Stage 2: Subjects will be re-randomized to one of the three treatment arms.
- NVK-002 Concentration 2 (Type: EXPERIMENTAL): Stage 1: Subjects will be randomized to NVK-002 Concentration 2~Stage 2: Subjects will be re-randomized to one of the three treatment arms.
- Vehicle (Placebo) (Type: PLACEBO_COMPARATOR): Stage 1: Subjects will be randomized to Vehicle (Placebo)~Stage 2: Subjects will be re-randomized to one of the two experimental NVK-002 treatment arms

Based on this trial design, predict the completion outcome and termination type (if applicable).